logo-loader
viewGenetic Technologies

Genetic Technologies’ shares surge on launching promotional campaign

The company’s lead product is a risk assessment test for non-hereditary breast cancer.

a woman getting a breast examination
Genetic Technologies markets BREVAGenplus through its U.S. subsidiary

Genetic Technologies (ASX:GTG) has launched a three-month promotional campaign in conjunction with Breast Cancer Awareness Month which takes place throughout October 2017.

The company’s shares were last trading 33% higher intra-day, at US$0.008.

Genetic Technologies’ lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

The test assesses both clinical risk factors and genetic markers known to be associated with non-hereditary breast cancer to determine a woman's five-year risk of developing the disease.

As part of the promotion, the BREVAGenplus test will be offered at a special reduced price of US$199.00 compared to its standard list price of US$349.00.

In April 2017, BREVAGenplus was repositioned from a traditional reimbursement system, through insurance providers, to a direct patient self-pay program.

The initiative was implemented to better serve healthcare providers and patients by providing a streamlined, easy to use billing and payment system.

Genetic Technologies markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres.

The company also markets to obstetricians/gynaecologists and breast cancer risk assessment specialists.

Quick facts: Genetic Technologies

Price: 0.005 AUD

ASX:GTG
Market: ASX
Market Cap: $15.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioLargo CEO 'proud, but not satisfied' as revenue climbs in...

BioLargo Inc (OTCMKTS:BLGO) CEO Dennis Calvert tells Proactive he is 'proud, but not satisfied' with 3Q revenue that soared 93% year-over-year on the back of the company’s Odor-No-More and BioLargo Engineering divisions. Among 3Q highlights, Calvert says its engineering division has become...

1 hour, 10 minutes ago

2 min read